Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.

paper Cited Public

Authors: Ashenhurst, James R; Bujarski, Spencer; Ray, Lara A
Year: 2012
Journal: Pharmacology, biochemistry, and behavior
PMID: 22954510
DOI: 10.1016/j.pbb.2012.08.019
PMCID: PMC3683577

#	Section	Preview
0	1. Introduction	Alcohol abuse and dependence represent a sizeable public health problem in the United States, with…
1	1. Introduction	reduces the number of drinking days (O’Malley et al., 1992, Volpicelli et al., 1992) and the…
2	1. Introduction	Alcohol has a complex pharmacological profile involving affinity for multiple receptor types; the…
3	1. Introduction	Prior pharmacogenetic studies have focused on the OPRM1 gene, which codes for mu-opioid receptors,…
4	1. Introduction	Pharmacogenetic studies of the A118G SNP have found that G-allele carriers exhibit greater…
5	1. Introduction	While the primary focus of pharmacogenetic studies has been on the mu class of opioid receptors,…
6	1. Introduction	As naltrexone has activity at multiple opioid receptor classes, it remains unknown where in the…
7	1. Introduction	rats (Kemppainen et al., 2012). These data stand in contrast to other studies examining delta and…
8	1. Introduction	While the specific dynamics of this circuit have yet to be resolved, these preclinical findings…
9	1. Introduction	There are several known polymorphisms in this larger family of opioid receptors that may inform…
10	1. Introduction	known functional polymorphisms in the OPRD1 and OPRK1 genes, a tSNP approach was used to provide…
11	2. Method — 2.1 Participants	Participants were recruited from the Boulder, Colorado community using print and online…
12	2. Method — 2.1 Participants	The final sample of study completers consisted of forty (12 female) non-treatment seeking heavy…
13	2. Method — 2.2 Screening and Experimental Procedures	Initial assessment for the inclusion criteria was conducted through a telephone interview, after…
14	2. Method — 2.2 Screening and Experimental Procedures	(GCRC) in order to ensure that participants were in good physical health and were medically eligible…
15	2. Method — 2.3 Alcohol Administration	In order to control dosage of alcohol during the alcohol challenge, an intravenous administration…
16	2. Method — 2.4 Medication	Medication (naltrexone 50 mg or matched placebo) was administered in a double-blind and crossover…
17	2. Method — 2.5 SNP Selection and Sequencing	Bioinformatics resources and results from the International HapMap Project were used to identify tag…
18	2. Method — 2.5 SNP Selection and Sequencing	For sequencing purposes, genomic DNA was collected and isolated from buccal cells following…
19	2. Method — 2.6 Measures	During the in-person assessment session, participants completed a battery of individual difference…

Name	Type
A118G SNP	variant
A allele	cohort
African American	cohort
alcohol	phenotype
alcohol abuse	phenotype
alcohol dependence	phenotype
Alcohol dependent human subjects local	cohort
Alcohol high local	phenotype
alcohol-induced sedation local	phenotype
Alcohol-induced sedation local	phenotype
alcoholism	phenotype
alcohol sensitivity	phenotype
alcohol stimulation	phenotype
Alcohol urge questionnaire	phenotype
Alcohol Use Disorder	phenotype
Alcohol Use Disorders Identification Test (AUDIT) local	phenotype
Asian	cohort
AUDIT	phenotype
Biphasic Alcohol Effects Scale	phenotype
Boulder, Colorado community participants local	cohort
BrAC	phenotype
breath alcohol concentration (BrAC) local	phenotype
Chinese	cohort
clinical study of naltrexone local	cohort
Combine Study	cohort
confusion	phenotype
craving	phenotype
craving effects local	phenotype
CTOP local	drug
DAMGO	drug
delta opioid agonist local	drug
delta opioid receptor	drug
dopamine	drug
DRD2	gene
drinking	phenotype
Drinks per drinking episode local	phenotype
Endogenous opioid local	drug
ethanol consumption	phenotype
ethanol preference	phenotype
European ancestry	cohort
fatigue	phenotype
G allele	variant
GCRC local	cohort
genomic DNA	drug
HapMap	cohort
hazardous drinking	phenotype
heavy drinking	phenotype
Hispanic	phenotype
kappa agonist local	drug
kappa opioid receptor	drug
Liking local	phenotype
medication	drug
mice	cohort
midbrain	anatomy
morphine	drug
mu opioid receptor	drug
naloxone	drug
naltrexone	drug
Naltrexone clinical trials local	cohort
Naltrindole local	drug
nucleus accumbens	anatomy
opioid receptor SNPs local	variant
Oprd1	cohort
OPRD1^1 local	variant
OPRD1^2 local	variant
OPRD1^3 local	variant
OPRD1^5 local	variant
OPRD1 G allele local	variant
OPRK local	gene
OPRK1	cohort
OPRK1^1 local	variant
OPRK1 C allele local	variant
OPRK1 SNP local	variant
OPRK^2 local	variant
OPRM1	cohort
OPRM1 A118G	cohort
OPRM1 A118G SNP local	variant
participants	cohort
pharmacogenetic response local	phenotype
placebo-controlled laboratory study of naltrexone local	cohort
rats	cohort
Reinforcing effects local	phenotype
relapse	phenotype
relapse rates	phenotype
riboflavin local	drug
rs2236856 local	variant
rs4654327	variant
rs499062 local	variant
rs508448 local	variant
rs529520 local	variant
rs581111 local	variant
rs678849 local	variant
rs6985606	variant
rs760588 local	variant
rs963549 local	variant
rs997917	variant
saline	drug
sedative effects	phenotype
sedatives	drug
sex	phenotype
stimulant effects	drug
stimulation	phenotype
study completers	cohort
study medication	drug
subjective intoxication	phenotype
time to relapse	phenotype
urine	drug
ventral pallidum	anatomy
ventral tegmental area	anatomy
Voluntary drinking local	phenotype
White	phenotype
whites	cohort
β-endorphin	drug

Citation	PMID	DOI	Status
Allen, JP et al., Alcohol Clin Exp Res, 1997, A review of research on the Alcohol Use Disorders Identification Test (AUDIT)	9194913	—	Cited
Ananthan, S et al., Journal of medicinal chemistry, 1999, Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans	10479286	10.1021/jm990039i	Cited
Anton, RF et al., Am J Psychiatry, 1999, Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial	10553740	10.1176/ajp.156.11.1758	Cited
Anton, RF et al., Arch Gen Psychiatry, 2008, An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study	18250251	10.1001/archpsyc.65.2.135	Cited
Anton, RF et al., JAMA, 2006, Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial	16670409	10.1001/jama.295.17.2003	Cited
Anton, RF et al., Psychopharmacology (Berl), 2004, Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking	14722705	10.1007/s00213-003-1720-7	Cited
Arias, A et al., Drug Alcohol Depend, 2006, Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis	16387451	10.1016/j.drugalcdep.2005.11.024	Cited
Balldin, J et al., Alcohol Clin Exp Res, 2003, A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence	12878920	10.1097/01.ALC.0000075548.83053.A9	Cited
Barrett, JC et al., Bioinformatics, 2005, Haploview: analysis and visualization of LD and haplotype maps	15297300	10.1093/bioinformatics/bth457	Cited
Benjamin, D et al., Brain Res, 1993, Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats	7693299	10.1016/0006-8993(93)90309-b	Cited
Beyer, A et al., J Neurochem, 2004, Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor	15086512	10.1111/j.1471-4159.2004.02340.x	Cited
Bohn, MJ et al., Alcoholism, clinical and experimental research, 1995, Development and initial validation of a measure of drinking urges in abstinent alcoholics	7573780	10.1111/j.1530-0277.1995.tb01554.x	Cited
Bond, C et al., Proc Natl Acad Sci U S A, 1998, Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction	9689128	10.1073/pnas.95.16.9608	Cited
Chick, J et al., Alcohol Alcohol, 2000, A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse	11093966	10.1093/alcalc/35.6.587	Cited
Coller, JK et al., Pharmacogenet Genomics, 2011, OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence	21946895	10.1097/FPC.0b013e32834c5445	Cited
Del Boca, FK et al., Alcohol Clin Exp Res, 1996, Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer	8947318	10.1111/j.1530-0277.1996.tb01142.x	Cited
Drobes, DJ et al., Alcohol Clin Exp Res, 2004, Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers	15365307	10.1097/01.alc.0000139704.88862.01	Cited
Emmerson, PJ et al., The Journal of pharmacology and experimental therapeutics, 1994, Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes	7996478	—	Cited
Freeman, B et al., Behav Genet, 1997, DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations	9210796	10.1023/a:1025614231190	Cited
Gelernter, J et al., Alcoholism, clinical and experimental research, 2007, Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study	17374034	10.1111/j.1530-0277.2007.00339.x	Cited
Gianoulakis, C et al., Arch Gen Psychiatry, 1996, Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism	8611062	10.1001/archpsyc.1996.01830030072011	Cited
Goldman, D et al., J Stud Alcohol Suppl, 2005, COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms	16223057	10.15288/jsas.2005.s15.56	Cited
Grant, BF et al., Drug Alcohol Depend, 2004, The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002	15194200	10.1016/j.drugalcdep.2004.02.004	Cited
Guardia, J et al., Alcohol Clin Exp Res, 2002, A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial	12351933	10.1097/01.ALC.0000030561.15921.A9	Cited
Heinala, P et al., J Clin Psychopharmacol, 2001, Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial	11386491	10.1097/00004714-200106000-00006	Cited
Hyytia, P et al., Alcohol Clin Exp Res, 2001, Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats	11198711	10.1111/j.1530-0277.2001.tb02123.x	Cited
Kemppainen, H et al., Alcohol Clin Exp Res, 2012, Opioidergic modulation of ethanol self-administration in the ventral pallidum	21895714	10.1111/j.1530-0277.2011.01611.x	Cited
Kiefer, F et al., Arch Gen Psychiatry, 2003, Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study	12511176	10.1001/archpsyc.60.1.92	Cited
Killeen, TK et al., Alcohol Clin Exp Res, 2004, Effectiveness of naltrexone in a community treatment program	15547458	10.1097/01.alc.0000145688.30448.2c	Cited
King, AC et al., Psychopharmacology (Berl), 1997, Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence	9122358	10.1007/s002130050156	Cited
Ko, MC et al., The Journal of pharmacology and experimental therapeutics, 1998, Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys	9580592	—	Cited
Koistinen, M et al., Alcohol Clin Exp Res, 2001, Naltrexone suppresses ethanol intake in 6-hydroxydopamine-treated rats	11707635	—	Cited
Kranzler, HR et al., Neuropsychopharmacology, 2000, Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial	10731624	10.1016/S0893-133X(99)00135-9	Cited
Krystal, JH et al., N Engl J Med, 2001, Naltrexone in the treatment of alcohol dependence	11742047	10.1056/NEJMoa011127	Cited
Latt, NC et al., Med J Aust, 2002, Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting	12064984	10.5694/j.1326-5377.2002.tb04550.x	Cited
Lee, MC et al., J Nucl Med, 1988, Duration of occupancy of opiate receptors by naltrexone	2839637	—	Cited
Lench, N et al., Lancet, 1988, Simple non-invasive method to obtain DNA for gene analysis	2898042	10.1016/s0140-6736(88)92178-2	Cited
Littleton, J et al., Am J Addict, 2003, Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence	14972776	10.1111/j.1521-0391.2003.tb00492.x	Cited
MacKillop, J, Alcoholism, clinical and experimental research, 2006, Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state	16899034	10.1111/j.1530-0277.2006.00159.x	Cited
Mansour, A et al., Trends Neurosci, 1988, Anatomy of CNS opioid receptors	2465635	10.1016/0166-2236(88)90093-8	Cited
Martin, CS et al., Alcohol Clin Exp Res, 1993, Development and validation of the Biphasic Alcohol Effects Scale	8452195	10.1111/j.1530-0277.1993.tb00739.x	Cited
McCaul, ME et al., Neuropsychopharmacology, 2001, Naltrexone dampens ethanol-induced cardiovascular and hypothalamic- pituitary-adrenal axis activation	11557167	10.1016/S0893-133X(01)00241-X	Cited
Mitchell, JM et al., Sci Transl Med, 2012, Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens	22238334	10.1126/scitranslmed.3002902	Cited
Monti, PM et al., Alcohol Clin Exp Res, 2001, Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes	11707638	—	Cited
Morris, PL et al., Addiction, 2001, Naltrexone for alcohol dependence: a randomized controlled trial	11784454	10.1046/j.1360-0443.2001.961115654.x	Cited
Oslin, DW et al., Neuropsychopharmacology, 2003, A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients	12813472	10.1038/sj.npp.1300219	Cited
O’Malley, SS et al., Arch Gen Psychiatry, 1992, Naltrexone and coping skills therapy for alcohol dependence. A controlled study	1444726	10.1001/archpsyc.1992.01820110045007	Cited
Phillips, TJ et al., Nature neuroscience, 1998, Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors	10196569	10.1038/2843	Cited
Ray, LA et al., Addict Behav, 2006, Risk factors for alcohol misuse: examining heart rate reactivity to alcohol, alcohol sensitivity, and personality constructs	16466861	10.1016/j.addbeh.2006.01.010	Cited
Ray, LA et al., Alcohol Clin Exp Res, 2004, A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans	15608594	10.1097/01.alc.0000148114.34000.b9	Cited
Ray, LA et al., Alcohol Clin Exp Res, The Role of the Asn40Asp Polymorphism of the Mu Opioid Receptor Gene (OPRM1) on Alcoholism Etiology and Treatment: A Critical Review	21895723	10.1111/j.1530-0277.2011.01633.x	Cited
Ray, LA et al., Arch Gen Psychiatry, 2007, Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study	17768272	10.1001/archpsyc.64.9.1069	Cited
Ray, LA et al., Neuropsychopharmacology, Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study	21900886	10.1038/npp.2011.192	Cited
Rubio, G et al., J Subst Abuse Treat, 2002, Naltrexone improves outcome of a controlled drinking program	12495798	10.1016/s0740-5472(02)00296-9	Cited
Shoemaker, WJ et al., Behav Brain Res, 2002, The acquisition and maintenance of voluntary ethanol drinking in the rat: effects of dopaminergic lesions and naloxone	12445720	10.1016/s0166-4328(02)00290-5	Cited
Swift, RM et al., Am J Psychiatry, 1994, Naltrexone-induced alterations in human ethanol intoxication	8092339	10.1176/ajp.151.10.1463	Cited
Takemori, AE et al., Annu Rev Pharmacol Toxicol, 1992, Selective naltrexone-derived opioid receptor antagonists	1318671	10.1146/annurev.pa.32.040192.001323	Cited
Takemori, AE et al., J Pharmacol Exp Ther, 1988, Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays	2839664	—	Cited
Tate, SK et al., Nat Genet, 2004, Will tomorrow’s medicines work for everyone?	15508001	10.1038/ng1437	Cited
Tidey, JW et al., Alcoholism, clinical and experimental research, 2008, Moderators of naltrexone’s effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment	18028530	10.1111/j.1530-0277.2007.00545.x	Cited
van Rijn, RM et al., J Pharmacol Exp Ther, 2010, Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety	20605909	10.1124/jpet.110.170969	Cited
Volpicelli, JR et al., Arch Gen Psychiatry, 1992, Naltrexone in the treatment of alcohol dependence	1345133	10.1001/archpsyc.1992.01820110040006	Cited
Volpicelli, JR, J Clin Psychiatry, 2001, Alcohol abuse and alcoholism: an overview	11584874	—	Cited
Walker, AH et al., Environ Health Perspect, 1999, Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays	10378997	10.1289/ehp.99107517	Cited
Weerts, EM et al., Neuropsychopharmacology, 2008, Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects	17487229	10.1038/sj.npp.1301440	Cited
Zhang, H et al., Mol Psychiatry, 2008, The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk	17622222	10.1038/sj.mp.4002035	Cited
Zhang, Y et al., J Biol Chem, 2005, Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G	16046395	10.1074/jbc.M504942200	Cited

In this knowledge base

Title	Year	PMID
A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity.	2018	29623680
Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.	2017	28425121

External

Title	Authors	Journal	Year	Link
Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers.	Farahbakhsh ZZ et al.	—	2026	→
Introduction: Approved treatments for alcohol use disorder by regulatory agencies.	Camarini R et al.	—	2024	→
Association of <i>OPRK1</i> rs963549 and rs997917 polymorphisms with opioid use disorder and related phenotypes.	Özkan-Kotiloğlu S et al.	—	2023	→
Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms.	Özkan-Kotiloğlu S et al.	—	2023	→
Alcohol Use Disorder: Neurobiology and Therapeutics.	Yang W et al.	—	2022	→
KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.	Estave PM et al.	—	2022	→
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.	Terasaki D et al.	—	2022	→
Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations.	Lashgari NA et al.	—	2021	→
Developmental Considerations for the Use of Naltrexone in Children and Adolescents.	Stancil SL et al.	—	2021	→
Haplotype-based association study of Opioid Receptor Kappa-type 1 (OPRK1) gene polymorphisms with nicotine dependence among male smokers.	Albonaim A et al.	—	2021	→
Overview of Genetic Analysis of Human Opioid Receptors.	Spampinato SM	—	2021	→
On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.	Nieto SJ et al.	—	2020	→
Pharmacotherapies and personalized medicine for alcohol use disorder: a review.	Lohoff FW	—	2020	→
Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial.	Roche DJO et al.	—	2019	→
Pharmacogenetics of alcohol addiction: current perspectives.	Zastrozhin MS et al.	—	2019	→
Pharmacogenetics of alcohol use disorder treatments: an update.	Hartwell EE et al.	—	2019	→
The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving.	de Laat B et al.	—	2019	→
A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity.	Schuckit MA	—	2018	→
Delta Opioid Pharmacology in Relation to Alcohol Behaviors.	Alongkronrusmee D et al.	—	2018	→
Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population.	Albonaim A et al.	—	2017	→
Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.	Anderson RI et al.	—	2017	→
Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development.	Courtney KE et al.	—	2016	→
From genetic studies to precision medicine in alcohol dependence.	Sun Y et al.	—	2016	→
Nociceptin/orphanin FQ receptor gene variation is associated with smoking status in Japanese.	Kasai S et al.	—	2016	→
Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.	Berrettini W	—	2016	→
Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine.	Soyka M et al.	—	2016	→
Clinically relevant genetic biomarkers from the brain in alcoholism with representation on high resolution chromosome ideograms.	Manzardo AM et al.	—	2015	→
Subjective response as a consideration in the pharmacogenetics of alcoholism treatment.	Roche DJ et al.	—	2015	→
The pharmacogenetics of alcohol use disorder.	Jones JD et al.	—	2015	→
Alcohol-medical drug interactions.	Johnson BA et al.	—	2014	→
Challenges in paediatric procedural sedation: political, economic, and clinical aspects.	Mason KP	—	2014	→
Genetics and genomics of alcohol sensitivity.	Morozova TV et al.	—	2014	→
Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.	Courtney KE et al.	—	2014	→
Nalmefene for the treatment of alcohol dependence: a current update.	Soyka M	—	2014	→
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.	Sobczak M et al.	—	2014	→
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.	Crist RC et al.	—	2013	→
A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk.	Xu K et al.	—	2013	→
Endogenous opiates and behavior: 2012.	Bodnar RJ	—	2013	→
Opioid system genes in alcoholism: a case-control study in Croatian population.	Cupic B et al.	—	2013	→